belantamab mafodotin
gsk
['belantamab,mafodotin', 'dreamm', 'multiple myeloma', 'belantamab']
no evidence of bcma expression loss or systemic immune impairment after treatment with the bcma-targeted antibody-drug conjugate (adc) belantamab mafodotin (belamaf) in the dreamm-1 and dreamm-2 trials of patients with relapsed/refractory multiple myeloma (rrmm) #ash22 #myeloma 
Hematology is in my ??. Posts are mine. Mayo Clinic Associate, Asst Prof, BMT RNCC, RN Navigator, emeritus. IMF NLB. MM KOL. Patient educator & advocate.